UNSPSC 51334310: Clopenthixol decanoate

This classification denotes a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2HFX55AF4Y, chemically known as clopenthixol decanoate, (e/z)-, but more generally known as clopenthixol decanoate, which bears US NIH Compound Identifier 6450313. European Medicines Agency schedules Clopenthixol decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01364MIG. Most nations, for tariff and trade purposes, schedule clopenthixol decanoate under HS 29349990 and SITC 51579.

SMILES: As of Q4 2014, CLOPENTHIXOL DECANOATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51334310 Clopenthixol decanoate is a Commodity code that nominally identifies a specific antipsychotic injection, but recent state and local procurement activity under this code shows little alignment with the pharmaceutical product name. The code appears in recent opportunities focused on broader pharmaceutical procurement and drug-response supply chains rather than clopenthixol decanoate specifically. State and local buyers using this code are pursuing naloxone and drug deactivation systems, generic multi-source pharmaceuticals through cooperative purchasing, and exploratory direct-to-manufacturer pharmacy programs. Issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The procurement vehicles range from competitive sealed bids (IFB) to requests for information (RFI) and formal requests for proposal (RFP), reflecting the varied contracting approaches state and local governments employ for pharmaceutical supply.

Geographic activity centers on Florida, Texas, and Minnesota, with Minnesota's multistate cooperative alliance (MMCAP) extending procurement reach across participating jurisdictions including Oregon. Recent representative opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's S1070000015802 RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers with awards effective July 1, 2026. The code shows minimal activity tied to clopenthixol decanoate as a distinct therapeutic product; procurement professionals should verify code accuracy against actual procurement scope before pursuing opportunities tagged under this classification.